Reference priceEUR €577.50Original source price: INR 52,500.00. Converted estimates are available by currency selection.
| Brand | Pemazyre |
|---|---|
| Manufacturer | INCYTE BIOSCIENCES IBERIA S.L. |
| Prescription required | Yes |
Pemazyre 13.5mg Comprimidos,14 x 1(Pemigatinib)
Pemigatinib
Description
Pemazyre 13.5mg Comprimidos,14 x 1(Pemigatinib) is a medicine catalog record in the MediPriceHub database. Active ingredient: Pemigatinib. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: INCYTE BIOSCIENCES IBERIA S.L.. Therapeutic category: Medicine Library > Oncology Medicines > Bile duct cancer, bile duct cancer drugs. Pack information: 13.5 / 14. Origin country or market: Spain. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.Benefits
PEMAZYRE is a kinase inhibitor indicated: for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). For the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement.How to Use
Use Pemigatinib under the supervision of a qualified healthcare professional. Take it by mouth only according to the approved label and the dose prescribed by a qualified healthcare professional. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.Specification
Active ingredient: Pemigatinib. Pack size: 13.5 / 14. Pack unit: box. Manufacturer: INCYTE BIOSCIENCES IBERIA S.L.. Origin country: Spain. Source category: Medicine Library > Oncology Medicines > Bile duct cancer, bile duct cancer drugs. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.Side Effects
Cancer medicines may cause fatigue, nausea, vomiting, diarrhea or constipation, appetite changes, mouth sores, rash, changes in blood counts, infection risk, liver or kidney test changes, bleeding risk, neuropathy, infusion reactions, or organ-specific toxicity depending on the medicine. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, confusion, serious bleeding, signs of infection, or rapidly worsening symptoms. The approved local prescribing information is the controlling source for the complete adverse-reaction profile.Diese Angaben dienen nur als Referenz. Lassen Sie sich vor der Anwendung eines Medikaments von medizinischem Fachpersonal beraten.